Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Oppenheimer’s Colin Rusch on Wolfspeed shares: There’s substantial upside to earnings growth
Colin Rusch, Oppenheimer, joins ‘Closing Bell’ to discuss Wolfspeed shares turning positive on the year.
Boeing investigation: 171 of 218 Max-9 planes grounded with door plug issues
CNBC’s Phil LeBeau reports on the latest news from Boeing.
China seems to think that it is ‘out of the woods’: Professor
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Edmund Phelps of Columbia University says China seems to think that it has solved its problems, and its economy will see a return to “somewhat higher” growth rates. He also says China could “break loose” with a long wave of rapid innovation….
Watch CNBC’s full interview with Wells Fargo’s Ike Boruchow
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Ike Boruchow, Wells Fargo Securities senior equity analyst, joins ‘Power Lunch’ to discuss why he now believes there’s a rebound in the retail sector, what he would be buying right now and more. 04:02 Thu, Oct 20 20223:00 PM EDT
Bitcoin is ‘fair for everybody’, says Bitgo CEO Mike Belshe on spot bitcoin ETFs
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fred Thiel, Marathon Digital CEO and Mike Belshe, Bitgo CEO, joins ‘Closing Bell Overtime’ to talk the kick off of spot bitcoin ETF trading after SEC approval.
CNBC Pro Talks: Top strategists and stock pickers share their 2024 market playbook
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The S&P 500 ended 2023 with a bang, up 24% on the year despite persistent recession warnings, a regional banking crisis, widespread tech layoffs, and ‘higher-for-longer’ interest rates. Can the stock market momentum continue into 2024? Can the rally broaden out past…
